Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-12-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerequalstagehearther2
  Phrases that lowered it: times theaminotransferasethan timesthe upperarm
• Sponsor's past termination rate: 23.3% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.4% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 77.6% (lowers risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 199147 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 39517 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 16 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery NCT01106898 · started 2010 · scored riskier than 96% of active trials completed
• Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer NCT01750073 · started 2012 · scored riskier than 95% of active trials completed
• Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer NCT00629499 · started 2008 · scored riskier than 79% of active trials completed
• The Synergism Or Long Duration (SOLD) Study NCT00593697 · started 2008 · scored riskier than 51% of active trials completed
• Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer NCT06513364 · started 2024 · scored riskier than 67% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.